AMERICAN CLINICAL LABORATORY ASSN lobbying for AMERICAN CLINICAL LABORATORY ASSN

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 15, 2026

Expenses

$850,000

What this organization spent lobbying with its own staff. Reported using IRS section 162(e) definitions (method C): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

LAURA STEVENS KENT

Previously held: Dep. Chief, Appr. Dir., LD, Sr. LA, Rep. Charlie Dent; LA, Rep. Jim Greenwood

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Medicare/Medicaid

Issues related to reimbursement and coverage for clinical laboratory services, including the Medicare clinical laboratory fee schedule; implementation of the Protecting Access to Medicare Act (P.L. 113-93) and Consolidated Appropriations Act, 2026 (P.L. 119-75); RESULTS Act (H.R. 5269/S. 2761); laboratory coding, pricing, coverage, and payment; Improving Seniors' Timely Access to Care Act (H.R. 3514/S. 1816); Prior Authorization Accountability Act (H.R. 9396); program integrity initiatives.

Medical/Disease Research/Clinical Labs

Issues related to reimbursement and coverage for clinical laboratory services, including the Medicare clinical laboratory fee schedule; implementation of the Protecting Access to Medicare Act (P.L. 113-93) and the Consolidated Appropriations Act, 2026 (P.L. 119-75); RESULTS Act (H.R. 5269/S. 2761); diagnostic regulatory reform; Enhancing CLIA Act (H.R. 8990); artificial intelligence in laboratory services; Timely Access to Coverage Decisions Act (H.R. 8500); laboratory services as Essential Health Benefits; laboratory coding, pricing, coverage, and payment.

Health Issues

Issues related to reimbursement and coverage for clinical laboratory services, including the Medicare clinical laboratory fee schedule; implementation of the Protecting Access to Medicare Act (P.L. 113-93) and the Consolidated Appropriations Act, 2026 (P.L. 119-75); RESULTS Act (H.R. 5269/S. 2761); diagnostic regulatory reform; Enhancing CLIA Act (H.R. 8990); laboratory services as Essential Health Benefits; Patients Deserve Price Tags Act (H.R. 5582/S. 2355); Lower Costs, More Transparency Act (H.R. 9393); Health Care Price Certainty for All Americans Act (H.R. 9645); Prices on the Wall Act of 2026 (H.R. 9390).

Immigration

H-1Bs for Physicians and Healthcare Workforce Act (H.R. 7961).

Bills named in this filing 13

H.R. 5269
RESULTS Act
S. 2761
RESULTS Act
H.R. 3514
Improving Seniors’ Timely Access to Care Act of 2025
S. 1816
Improving Seniors’ Timely Access to Care Act of 2025
H.R. 9396
Prior Authorization Accountability Act
H.R. 8990
Protect Domestic Oil and Gas Small Business Act of 2026
H.R. 8500
Timely Access to Coverage Decisions Act of 2026
H.R. 5582
Patients Deserve Price Tags Act
S. 2355
Patients Deserve Price Tags Act
H.R. 9393
Lower Costs, More Transparency Act of 2026
H.R. 9645
Health Care Price Certainty for All Americans Act
H.R. 9390
Prices on the Wall Act of 2026
H.R. 7961
H–1Bs for Physicians and the Healthcare Workforce Act